Reanalyses of ETHOS Triple Therapy Trial Must Consider Forced Discontinuation of Prior Treatment at Randomization.
作者信息
Ariel Amnon, Suissa Samy
机构信息
Asaf Clinic, Clalit Healthcare Services, Afula, Israel; and.
Centre for Clinical Epidemiology, Lady Davis Institute at the Jewish General Hospital, and Department of Epidemiology and Biostatistics, McGill University, Montreal, Quebec, Canada.
出版信息
Am J Respir Crit Care Med. 2025 Mar;211(3):525. doi: 10.1164/rccm.202409-1842LE.
Abstract
摘要
相似文献
1
Reanalyses of ETHOS Triple Therapy Trial Must Consider Forced Discontinuation of Prior Treatment at Randomization.对ETHOS三联疗法试验的重新分析必须考虑在随机分组时强制停用先前治疗。
Am J Respir Crit Care Med. 2025 Mar;211(3):525. doi: 10.1164/rccm.202409-1842LE.
2
PROMETHEUS: Long-Term Exacerbation and Mortality Benefits of Implementing Single-Inhaler Triple Therapy in the US COPD Population.普罗米修斯：在美国慢性阻塞性肺疾病人群中实施单吸入器三联疗法的长期病情加重和死亡率获益情况
J Health Econ Outcomes Res. 2023 Jan 24;10(1):20-27. doi: 10.36469/001c.55635. eCollection 2023.
3
Reduced All-Cause Mortality in the ETHOS Trial of Budesonide/Glycopyrrolate/Formoterol for Chronic Obstructive Pulmonary Disease. A Randomized, Double-Blind, Multicenter, Parallel-Group Study.ETHOS 研究中布地奈德/格隆溴铵/福莫特罗治疗慢性阻塞性肺疾病降低全因死亡率：一项随机、双盲、多中心、平行分组研究。
Am J Respir Crit Care Med. 2021 Mar 1;203(5):553-564. doi: 10.1164/rccm.202006-2618OC.
4
Cost-Effectiveness of Triple Therapy with Budesonide/Glycopyrronium/Formoterol Fumarate Dihydrate versus Dual Therapies in Moderate-to-Very Severe Chronic Obstructive Pulmonary Disease: United Kingdom Analysis Using the ETHOS Study.布地奈德/格隆溴铵/富马酸福莫特罗二水化合物三联疗法与中重度至极重度慢性阻塞性肺疾病的双重疗法相比的成本效益：ETHOS 研究的英国分析。
Int J Chron Obstruct Pulmon Dis. 2022 Nov 22;17:2987-3000. doi: 10.2147/COPD.S381138. eCollection 2022.
5
Triple therapy in COPD: understanding the data.慢性阻塞性肺疾病的三联疗法：解读相关数据。
ERJ Open Res. 2023 Jan 30;9(1). doi: 10.1183/23120541.00615-2022. eCollection 2023 Jan.
6
Mortality risk reduction with budesonide/glycopyrrolate/formoterol fumarate versus fluticasone furoate/umeclidinium/vilanterol in COPD: a matching-adjusted indirect comparison based on ETHOS and IMPACT.布地奈德/格隆溴铵/富马酸福莫特罗与糠酸氟替卡松/乌美溴铵/维兰特罗相比在慢性阻塞性肺疾病中降低死亡风险：基于ETHOS和IMPACT的匹配调整间接比较
Curr Med Res Opin. 2023 Oct;39(10):1395-1405. doi: 10.1080/03007995.2023.2247969. Epub 2023 Aug 29.
7
Reanalyses of randomized clinical trial data.重新分析随机临床试验数据。
JAMA. 2014 Sep 10;312(10):1024-32. doi: 10.1001/jama.2014.9646.
8
Improvements in lung function with budesonide/glycopyrrolate/formoterol fumarate metered dose inhaler dual therapies in patients with COPD: a sub-study of the ETHOS trial.在 COPD 患者中，布地奈德/格隆溴铵/福莫特罗富马酸酯干粉吸入剂双联治疗改善肺功能：ETHOS 试验的一项亚研究。
Ther Adv Respir Dis. 2021 Jan-Dec;15:17534666211034329. doi: 10.1177/17534666211034329.
9
Triple Therapy with Budesonide/Glycopyrronium/Formoterol Fumarate Dihydrate versus Dual Therapies for Patients with COPD and Phenotypic Features of Asthma: A Pooled Post Hoc Analysis of KRONOS and ETHOS.布地奈德/格隆溴铵/富马酸福莫特罗二水合物三联疗法与双重疗法治疗慢性阻塞性肺疾病合并哮喘表型特征患者的比较：KRONOS和ETHOS的汇总事后分析
Int J Chron Obstruct Pulmon Dis. 2024 Dec 12;19:2729-2737. doi: 10.2147/COPD.S478349. eCollection 2024.
10
Relationship between prior inhaled corticosteroid use and benefits ofbudesonide/glycopyrronium/formoterol fumarate dihydrate on exacerbations, symptoms, health-related quality of life, and lung function in patients with chronic obstructive pulmonary disease: Analyses from the ETHOS study.在慢性阻塞性肺疾病患者中，先前使用吸入性皮质类固醇与布地奈德/格隆溴铵/富马酸福莫特罗二水化合物对加重、症状、健康相关生活质量和肺功能的获益之间的关系：来自 ETHOS 研究的分析。
Respir Med. 2022 Jun;197:106857. doi: 10.1016/j.rmed.2022.106857. Epub 2022 Apr 22.
本文引用的文献
1
Effect of Triple Therapy on Cardiovascular and Severe Cardiopulmonary Events in Chronic Obstructive Pulmonary Disease: A Analysis of a Randomized, Double-Blind, Phase 3 Clinical Trial (ETHOS).三联疗法对慢性阻塞性肺疾病心血管及严重心肺事件的影响：一项随机、双盲、3期临床试验（ETHOS）分析
Am J Respir Crit Care Med. 2025 Feb;211(2):205-214. doi: 10.1164/rccm.202312-2311OC.
2
Relationship between prior inhaled corticosteroid use and benefits ofbudesonide/glycopyrronium/formoterol fumarate dihydrate on exacerbations, symptoms, health-related quality of life, and lung function in patients with chronic obstructive pulmonary disease: Analyses from the ETHOS study.在慢性阻塞性肺疾病患者中，先前使用吸入性皮质类固醇与布地奈德/格隆溴铵/富马酸福莫特罗二水化合物对加重、症状、健康相关生活质量和肺功能的获益之间的关系：来自 ETHOS 研究的分析。
Respir Med. 2022 Jun;197:106857. doi: 10.1016/j.rmed.2022.106857. Epub 2022 Apr 22.
3
Perplexing mortality data from triple therapy trials in COPD.慢性阻塞性肺疾病三联疗法试验中令人困惑的死亡率数据。
Lancet Respir Med. 2021 Jul;9(7):684-685. doi: 10.1016/S2213-2600(21)00238-1. Epub 2021 Jun 11.
4
Reduced All-Cause Mortality in the ETHOS Trial of Budesonide/Glycopyrrolate/Formoterol for Chronic Obstructive Pulmonary Disease. A Randomized, Double-Blind, Multicenter, Parallel-Group Study.ETHOS 研究中布地奈德/格隆溴铵/福莫特罗治疗慢性阻塞性肺疾病降低全因死亡率：一项随机、双盲、多中心、平行分组研究。
Am J Respir Crit Care Med. 2021 Mar 1;203(5):553-564. doi: 10.1164/rccm.202006-2618OC.
5
Triple therapy in COPD: only for the right patient.慢性阻塞性肺疾病的三联疗法：仅适用于合适的患者。
Eur Respir J. 2019 Apr 18;53(4). doi: 10.1183/13993003.00394-2019. Print 2019 Apr.
6
Fluticasone furoate and vilanterol and survival in chronic obstructive pulmonary disease with heightened cardiovascular risk (SUMMIT): a double-blind randomised controlled trial.氟替卡松酯和维兰特罗与心血管风险升高的慢性阻塞性肺疾病患者的生存关系（SUMMIT）：一项双盲随机对照试验。
Lancet. 2016 Apr 30;387(10030):1817-26. doi: 10.1016/S0140-6736(16)30069-1. Epub 2016 Apr 28.
Zotero 插件